EARLY CLOSURE MARCH 4 - Due to the forecast for severe winter weather, Creighton's Omaha campus will close at 7 P.M. this evening.
All in-person classes, clinics, and events, regardless of start time, are asked to end by 7 P.M. For those needing a shuttle, please visit my.creighton.edu for the most up-to-date maps and schedule. Shuttles will run until 8 P.M. this evening. We encourage you to be mindful of other closures or impacted services across the city as well.
Employees, including those classified as responsible for “essential operations” should review Creighton's Weather and Emergency-Related Absence Policy and work with your immediate supervisor on expectations for job functions during this curtailment of campus operations.
Please take proper winter weather precautions throughout the day and contact public safety at 402.280.2911 for any emergencies.
Board certified in Internal Medicine and Pulmonary Disease
Areas of Interest: Critical care/cardiac arrest simulation training, COPD/asthma, lung cancer diagnosis
Pulmonary and Critical Care Medicine Fellowship: Creighton University School of Medicine, Omaha, NE
Residency: SSM Saint Mary’s Health Center, St. Louis, MO
Medical School: American University of Antigua College of Medicine
Medicine
Associate Professor
Sub Investigator - GSK COPD CTT116855: A phase III, 52 week, randomized, double-blind, 3-arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF/UMEC/VI with the fixed dose dual combinations of FF/VI and UMEC/VI, al administered once-daily in the morning via a dry powder inhaler in subjects with chronic obstructive pulmonary disease
Sub Investigator - Insmed MAC: A Randomized, Open-Label, Multicenter Study of Liposomal Amikacin for Inhalation (LAI) in Adult Patients with Nontuberculous Mycobacterial (NTM) Lung Infections caused by Mycobacterium avium complex (MAC) that are refractory to treatment
Sub Investigator - Janssen: Medically Ill Patient Assessment of Rivaroxaban Versus Placebo IN Reducing Post-Discharge Venous Thrombo-Embolism Risk (MARINER)
Sub Investigator: CXA-NP-11-04: A Prospecteive, Randomized, Double Blind, Multicenter, Phase III Study to Assess the Safety and Efficacy of Intravenous Ceftolozane/Tazobactam Compared with Meropenem in Adult Patients with Ventilated Nosocomial Pneumonia.
Sub Investigator AstraZeneca: Double-Blind, Randomized, Placebo-controlled, Parallel-group, Phase IV Study to Evaluate the Effect of Aclidinuim Bromide on Long-Term Cardiovascular Safety and COPD Exacerbations in Patients with Moderate to Very Severe COPD (ASCENT COPD)
Sub Investigator - AstraZeneca: A Randomized, Double-blind, double dummy, chronic dosing (56 week) Placebo-controlled, Parallel Group, Multicentre, Phase III Study to evaluate the efficacy and safety of 3 doses of Benralizumab in patients with moderate to very severe chronic
obstructive pulmonary disease with a history of COPD exacerbations